Li Wei Cho et al Ibanez L, de Zegher F, Potau N. 1998. Premature pubarche, ovarian hy- perandrogenism, hyperinsulinism and the polycystic ovary syndrome: from a complex constellation to a simple sequence of prenatal onset. J Endocrinol Invest, 21:558–66. Ibanez L, Valls C, Marcos MV, et al. 2004. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome:effects of prepubertal initiation and postpubertal dis- continuation of metformin treatment. J Clin Endocrinol Metab, 89:4331–7. Jayagopal V, Kilpatrick ES, Holding S, et al. 2005. Orlistat is as beneﬁcial as metformin in the treatment of polycystic ovarian syndrome. J Clin Endocrinol Metab, 90:729–33. Kawashima S, Yokoyama M. 2004. Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler Thromb Vasc Biol, 24:998–1005. Kelly CC, Lyall H, Petrie JR, et al. 2001. Low grade chronic inﬂamma- tion in women with polycystic ovarian syndrome. J Clin Endocrinol Metab, 86:2453–5. Kent SC, Legro RS. 2002. Polycystic ovary syndrome in adolescents Adolesc Med, 13:73–88, vi. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. 1989. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries:correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf), 31:757–63. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. 1998. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States:a prospective study. J Clin Endocrinol Metab, 83:3078–82. Lazurova I, Dravecka I, Kraus V, et al. 2004. Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. Bratisl Lek Listy, 105:207–10. Legro RS, Blanche P, Krauss RM, et al. 1999. Alterations in low-density lipoprotein and high-density lipoprotein subclasses among Hispanic women with polycystic ovary syndrome:inﬂuence of insulin and genetic factors. Fertil Steril, 72:990–5. Legro RS, Kunselman AR, et al. 2001. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med, 111:607–13. Lewandowski, et al. 2005. Mahabeer S, Jialal I, Norman RJ, et al. 1989. Insulin and C-peptide secre- tion in non-obese patients with polycystic ovarian disease. Horm Metab Res, 21:502–6. Mather KJ, Kwan F, Corenblum B. 2000. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk indepen- dent of obesity. Fertil Steril, 73:150–6. Meyer C, McGrath BP, Teede HJ. 2005. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab, 90:5711–16. Mohamed-Ali V, Pinkney JH, Coppack SW. 1998. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord, 22:1145–58. Muller-Wieland D, Kotzka J, Knebel, et al. 1998. Metabolic syndrome and hypertension:pathophysiology and molecular basis of insulin resistance. Basic Res Cardiol, 93(Suppl 2):131–4. Munir I, Yen HW, Baruth T, et al. 2005. Resistin stimulation of 17alpha-hy- droxylase activity in ovarian theca cells in vitro:relevance to polycystic ovary syndrome. J Clin Endocrinol Metab, 90:4852–7. NCEP/ATPIII. 2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 285:2486–97. Nestler JE, Jakubowicz DJ. 1997. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab, 82:4075–9. Nesto RW. 2003.The relation of insulin resistance syndromes to risk of cardiovascular disease. Rev Cardiovasc Med, 4(Suppl 6):S11–18. 62 Nonogaki K, Fuller GM, Fuentes NL, et al. 1995. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology, 136:2143–9. Norman RJ, Noakes M, Wu R, et al. 2004. Improving reproductive perfor- mance in overweight/obese women with effective weight management. Hum Reprod Update, 10:267–80. O‘Meara NM, Blackman JD, Ehrmann DA, et al. 1993. Defects in beta-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab, 76:1241–7. Orbetzova MM, Shigarminova RG, Genchev GG, et al. 2003. Role of 24-hour monitoring in assessing blood pressure changes in polycystic ovary syndrome. Folia Med (Plovdiv), 45:21–5. Orio F Jr, Palomba S, Cascella T, et al. 2005. Improvement in endothelial structure and function after metformin treatment in young normal- weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab, 90:6072–6. Panidis D, Koliakos G, Kourtis A, et al. 2004. Serum resistin levels in women with polycystic ovary syndrome. Fertil Steril, 81:361–6. Paradisi G, Steinberg HO, Hempﬂing A, et al. 2001. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation, 103:1410–15. Pekala P, Kawakami M, Vine W, et al. 1983. Studies of insulin resis- tance in adipocytes induced by macrophage mediator. J Exp Med, 157:1360–5. Potter van Loon BJ, Kluft C, Radder JK, et al. 1993. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism, 42:945–9. Ratner RE. 2006. An update on the Diabetes Prevention Program. Endocr Pract, 12(Suppl 1):20–4. Reaven GM. 1988. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes, 37:1595–607. Resnick LM. 1992. Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hypertension and related metabolic disorders. Am J Med, 93:11S–20S. Robinson S, Henderson AD, Gelding SV, et al. 1996. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries. Clin Endocrinol (Oxf), 44:277–84. Rondinone CM. 2006. Adipocyte-derived hormones, cytokines, and media- tors. Endocrine, 29:81–90. Sabuncu T, Harma M, Nazligul Y, et al. 2003. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil Steril, 80:1199–204. Sahin Y, Yirmibes U, Kelestimur F, et al. 2004. The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol, 113:214–20. Sampson M, Kong C, Patel A, et al. 1996. Ambulatory blood pressure proﬁles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endo- crinol (Oxf), 45:623–9. Sechi LA, Bartoli E. 1996. Molecular mechanisms of insulin resistance in arterial hypertension. Blood Press Suppl, 1:47–54. Seow KM, Juan CC, Wu L Y, et al. 2004. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. Hum Reprod, 19:48–53. Sepilian V, Nagamani M. 2005. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance. J Clin Endocrinol Metab, 90:60–5. Silfen ME, Denburg MR, Manibo AM, et al. 2003. Early endocrine, meta- bolic, and sonographic characteristics of polycystic ovary syndrome (PCOS):comparison between nonobese and obese adolescents. J Clin Endocrinol Metab, 88:4682–8. Sjoholm A, Nystrom T. 2005. Endothelial inﬂammation in insulin resistance. Lancet, 365:610–12. Solomon CG, Hu FB, Dunaif A, et al. 2002. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab, 87:2013–17. Vascular Health and Risk Management 2007:3(1)